Analysts Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $52.00

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average recommendation of “Hold” from the six analysts that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $52.00.

A number of research firms have recently weighed in on OMCL. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, November 27th. JPMorgan Chase & Co. upped their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Benchmark reiterated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Craig Hallum upped their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company raised their price objective on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th.

Omnicell Price Performance

Omnicell stock opened at $46.00 on Wednesday. The stock’s 50 day moving average price is $44.90 and its 200 day moving average price is $38.49. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74. The company has a market cap of $2.13 billion, a PE ratio of -117.95, a price-to-earnings-growth ratio of 35.64 and a beta of 0.77.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently bought and sold shares of OMCL. Assenagon Asset Management S.A. grew its holdings in shares of Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after buying an additional 228,093 shares in the last quarter. Federated Hermes Inc. raised its holdings in Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after acquiring an additional 909,480 shares during the last quarter. Royce & Associates LP purchased a new position in shares of Omnicell during the 3rd quarter worth $811,000. Intech Investment Management LLC acquired a new stake in shares of Omnicell during the third quarter worth $753,000. Finally, Liontrust Investment Partners LLP purchased a new stake in shares of Omnicell in the second quarter valued at $4,066,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.